Jie Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jie Zhang has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Ling Wu
Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
16 shared publications Xiaoyan Mao
Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
11 shared publicationsQiuyu Xu
Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
7 shared publicationsShuwen Qiu
5 shared publicationsDi Chen
Department of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Road, Shanghai 200011, China
3 shared publicationsHongyuan Gao
3 shared publications
Latest Publications
- 17 July 2026
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 43 (8) , 2679-2688
Novel mutations in NLRP2 and NLRP7 cause early embryonic arrest and female infertility
Early embryonic arrest is one of the reasons for the recurrent IVF/ICSI failures. We aimed to identify pathogenic mutations in female infertility patients with early embryonic arrest. Whole-exome sequencing was performed in the affected patients. Sanger sequencing was used on patients and their families to confirm the identified mutations. Wild-type and mutant plasmids were constructed and transfected into HeLa cells to investigate the functional effect of the identified mutations. We identified three novel homozygous mutations of NLRP2 (p.Arg81*, p.Lys312del, and p.Val316Ala) and compound heterozygous mutations with a novel frameshift mutation and a novel missense mutation of NLRP7 (p.Gln315Arg fs*5 and p.Ile830Thr) in the affected individuals with early embryonic arrest. Western blot in HeLa cells showed the mutations caused a significant decrease in NLRP2 and NLRP7 to a varying degree, which impaired the stability of the proteins. Immunofluorescent staining showed some mutations altered the localization of NLRP2 and NLRP7. This study identified novel mutations in NLRP2 and NLRP7, expanding the mutational and phenotypic spectrum of NLRP2 and NLRP7. Our findings also establish the foundation for genetic diagnosis in recurrent IVF/ICSI failure patients with early embryonic arrest.
- 17 July 2026
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 43 (8) , 2679-2688
Novel mutations in NLRP2 and NLRP7 cause early embryonic arrest and female infertility
Early embryonic arrest is one of the reasons for the recurrent IVF/ICSI failures. We aimed to identify pathogenic mutations in female infertility patients with early embryonic arrest. Whole-exome sequencing was performed in the affected patients. Sanger sequencing was used on patients and their families to confirm the identified mutations. Wild-type and mutant plasmids were constructed and transfected into HeLa cells to investigate the functional effect of the identified mutations. We identified three novel homozygous mutations of NLRP2 (p.Arg81*, p.Lys312del, and p.Val316Ala) and compound heterozygous mutations with a novel frameshift mutation and a novel missense mutation of NLRP7 (p.Gln315Arg fs*5 and p.Ile830Thr) in the affected individuals with early embryonic arrest. Western blot in HeLa cells showed the mutations caused a significant decrease in NLRP2 and NLRP7 to a varying degree, which impaired the stability of the proteins. Immunofluorescent staining showed some mutations altered the localization of NLRP2 and NLRP7. This study identified novel mutations in NLRP2 and NLRP7, expanding the mutational and phenotypic spectrum of NLRP2 and NLRP7. Our findings also establish the foundation for genetic diagnosis in recurrent IVF/ICSI failure patients with early embryonic arrest.
- 30 January 2026
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 43 (3) , 797-807
Vanishing twin syndrome and fetal reduction adversely affect perinatal outcomes following IVF-FET: an analysis based on 33,238 ongoing pregnancies
Purpose To assess the associations between vanishing twin (VT) and fetal reduction (FR) with obstetric and perinatal outcomes following in vitro fertilization (IVF)–frozen embryo transfer (FET). Methods This was a retrospective cohort study involving women who had undergone FR or experienced VT during the period from 2012 to 2022. Cohorts were stratified by timing into early (< 15 weeks) and late (≥ 15 weeks) VT/FR. Controls comprised primary singletons and non-reduced twins. The primary outcome measurements were maternal and birth complications. Results Among 33,238 ongoing pregnancies, there were 24,316 primary singletons, 7452 non-reduced twins, 1354 VTs, and 116 FRs. Multivariable analyses showed birth outcomes in the study groups were similar to or better than non-reduced twin deliveries. Compared to primary singletons, both early and late FRs were associated with increased risk of preterm birth (PTB); late FR also increased the risk of low birthweight (LBW). Early and late VTs similarly had higher risks of PTB and LBW versus primary singletons. Obstetric complications were generally comparable or lower in the study groups versus twin deliveries; however, late FR was linked to a higher risk of hypertensive disorders of pregnancy compared with primary singletons, and late VT was associated with increased abnormal placentation versus primary singletons and twins. Conclusions In this large IVF-FET cohort, most birth and maternal outcomes were comparable or better than in non-reduced twins, but certain complications remained more common in both VT and FR groups. Both exposures were linked to adverse perinatal outcomes versus primary singletons. Moreover, VT and FR appear to be more problematic when these occur later in pregnancy.
- 30 January 2026
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 43 (3) , 797-807
Vanishing twin syndrome and fetal reduction adversely affect perinatal outcomes following IVF-FET: an analysis based on 33,238 ongoing pregnancies
Purpose To assess the associations between vanishing twin (VT) and fetal reduction (FR) with obstetric and perinatal outcomes following in vitro fertilization (IVF)–frozen embryo transfer (FET). Methods This was a retrospective cohort study involving women who had undergone FR or experienced VT during the period from 2012 to 2022. Cohorts were stratified by timing into early (< 15 weeks) and late (≥ 15 weeks) VT/FR. Controls comprised primary singletons and non-reduced twins. The primary outcome measurements were maternal and birth complications. Results Among 33,238 ongoing pregnancies, there were 24,316 primary singletons, 7452 non-reduced twins, 1354 VTs, and 116 FRs. Multivariable analyses showed birth outcomes in the study groups were similar to or better than non-reduced twin deliveries. Compared to primary singletons, both early and late FRs were associated with increased risk of preterm birth (PTB); late FR also increased the risk of low birthweight (LBW). Early and late VTs similarly had higher risks of PTB and LBW versus primary singletons. Obstetric complications were generally comparable or lower in the study groups versus twin deliveries; however, late FR was linked to a higher risk of hypertensive disorders of pregnancy compared with primary singletons, and late VT was associated with increased abnormal placentation versus primary singletons and twins. Conclusions In this large IVF-FET cohort, most birth and maternal outcomes were comparable or better than in non-reduced twins, but certain complications remained more common in both VT and FR groups. Both exposures were linked to adverse perinatal outcomes versus primary singletons. Moreover, VT and FR appear to be more problematic when these occur later in pregnancy.
- 30 January 2026
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 52 (5) , 105525
PCOS in women with normal body mass index is not associated with adverse obstetric and perinatal outcomes after IVF-FET
- 30 January 2026
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 52 (5) , 105525
PCOS in women with normal body mass index is not associated with adverse obstetric and perinatal outcomes after IVF-FET
- 7 January 2026
- Published by Oxford University Press (OUP) in Molecular Human Reproduction
- Vol. 32 (1)
Orosomucoid 2 improves reproductive phenotypes in a mouse model of PCOS induced by letrozole under high-fat diet conditions
Polycystic ovary syndrome (PCOS) is the most common reproductive endocrine disorder among women of reproductive age. It is characterized by excess androgens, anovulation, and polycystic ovarian morphology, and is often accompanied by obesity, insulin resistance, and glucose metabolism abnormalities. Although PCOS is a complex disease with diverse and uncertain etiologies, metabolic dysfunction and adipose tissue abnormalities are critical components in its pathology. Previous studies have demonstrated that letrozole exposure combined with high-fat diet treatment in female mice produced key endocrine and metabolic features of PCOS, including elevated testosterone levels, anovulation, and adipocyte hypertrophy. Orosomucoid 2 (ORM2), an acute-phase protein predominantly secreted by hepatocytes, plays a regulatory role in metabolic balance and gut microbiota composition. This study aimed to investigate the effects of ORM2 levels on the metabolic and endocrine dysregulations associated with letrozole-induced PCOS in female mice. We established a letrozole-induced PCOS by treating mice with Let+HFD (letrozole and high-fat diet) for 5 weeks. Our findings revealed that compared to control females receiving placebo and high-fat diet treatment, females treated with Let+HFD exhibited significantly reduced hepatic Orm2 expression. Furthermore, Orm2 knockout mice subjected to Let+HFD treatment developed more severe ovarian pathology, higher testosterone levels, hepatocyte hypertrophy, and reduced Ucp1 expression in white adipose tissue compared to wild-type mice. Conversely, supplementation with recombinant ORM2 protein in females under Let+HFD treatment resulted in improved ovarian morphology, reduced hepatocyte cell size, and enhanced Ucp1 expression in white adipose tissue. Overall, this research identifies ORM2 as a promising therapeutic target for PCOS treatment.
- 7 January 2026
- Published by Oxford University Press (OUP) in Molecular Human Reproduction
- Vol. 32 (1)
Orosomucoid 2 improves reproductive phenotypes in a mouse model of PCOS induced by letrozole under high-fat diet conditions
Polycystic ovary syndrome (PCOS) is the most common reproductive endocrine disorder among women of reproductive age. It is characterized by excess androgens, anovulation, and polycystic ovarian morphology, and is often accompanied by obesity, insulin resistance, and glucose metabolism abnormalities. Although PCOS is a complex disease with diverse and uncertain etiologies, metabolic dysfunction and adipose tissue abnormalities are critical components in its pathology. Previous studies have demonstrated that letrozole exposure combined with high-fat diet treatment in female mice produced key endocrine and metabolic features of PCOS, including elevated testosterone levels, anovulation, and adipocyte hypertrophy. Orosomucoid 2 (ORM2), an acute-phase protein predominantly secreted by hepatocytes, plays a regulatory role in metabolic balance and gut microbiota composition. This study aimed to investigate the effects of ORM2 levels on the metabolic and endocrine dysregulations associated with letrozole-induced PCOS in female mice. We established a letrozole-induced PCOS by treating mice with Let+HFD (letrozole and high-fat diet) for 5 weeks. Our findings revealed that compared to control females receiving placebo and high-fat diet treatment, females treated with Let+HFD exhibited significantly reduced hepatic Orm2 expression. Furthermore, Orm2 knockout mice subjected to Let+HFD treatment developed more severe ovarian pathology, higher testosterone levels, hepatocyte hypertrophy, and reduced Ucp1 expression in white adipose tissue compared to wild-type mice. Conversely, supplementation with recombinant ORM2 protein in females under Let+HFD treatment resulted in improved ovarian morphology, reduced hepatocyte cell size, and enhanced Ucp1 expression in white adipose tissue. Overall, this research identifies ORM2 as a promising therapeutic target for PCOS treatment.
- Open Access
- 6 January 2026
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2026 (1)
Reply: non-significant results do not imply similarity or safety in NC-FET follicle-size comparisons: a clarification
- 6 January 2026
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2026 (1)
Open AccessReply: non-significant results do not imply similarity or safety in NC-FET follicle-size comparisons: a clarification
- Open Access
- 7 June 2025
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2025 (3) , hoaf047
Pregnancy and perinatal outcomes after modified natural cycle-frozen embryo transfers according to size of the dominant follicle on the hCG trigger day
STUDY QUESTION: Is there an association between the dominant follicle size on the day of the hCG ovulation trigger and reproductive, obstetric, and perinatal outcomes in modified natural cycle-frozen embryo transfer (NC-FET) cycles in which intensive luteal phase support (LPS) was utilized? SUMMARY ANSWER: The dominant follicle size on the day of triggering, ranging from above 10 to 18 mm or larger, was not associated with negative live birth or perinatal outcomes in modified NC-FETs when an intensive LPS was provided. WHAT IS KNOWN ALREADY: There is growing evidence concerning the optimal timing for triggering final oocyte maturation during IVF ovarian stimulation cycles to obtain mature oocytes. However, a consensus on the ideal follicle size for administering hCG in modified NC-FETs has yet to be established. Interestingly, it has been suggested that the presence of a mature oocyte may not be necessary for FET. STUDY DESIGN, SIZE, DURATION: A retrospective cohort study was conducted at a university-affiliated reproductive medicine center. The study included women with regular menstrual cycles who underwent autologous modified NC-FETs between 2013 and 2023 for potential analysis. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients were categorized into eight groups based on the size of the dominant follicle at the time of hCG administration: <12, 12–12.9, 13–13.9, 14–14.9, 15–15.9, 16–16.9, 17–17.9, and ≥18 mm. The primary outcome measured was the live birth rate (LBR), while secondary outcomes included the rates of positive pregnancy tests, implantation, clinical pregnancy, and pregnancy loss, as well as perinatal and obstetric complications. A generalized estimating equation logistic regression model was employed to account for the clustered nature of the data and to adjust for potential confounding factors. The group with a follicle size ≥18 mm was designated as the reference group in the logistic regression analyses. An intensive LPS, consisting of 40 mg dydrogesterone plus 400 mg vaginal progesterone, was adopted. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 14 431 cycles that met the inclusion criteria were analyzed. The LBRs were similar across the eight groups. Furthermore, there were no significant differences in LBRs when the reference group was compared to the other follicle-size categories in the unadjusted models. Even after adjusting for several key confounders, the LBRs remained comparable between the study cohorts and the reference controls. Additionally, other reproductive parameters, such as rates of positive pregnancy tests, implantation, clinical pregnancy, and pregnancy loss, showed similar results between the control group and all other groups in both the unadjusted and confounder-adjusted analyses. Finally, pregnancies derived from the other follicle-size groups did not show increased risks of adverse perinatal or obstetric outcomes when compared to the reference group, both before and after adjustment for covariates. LIMITATIONS, REASONS FOR CAUTION: The primary limitation of the current study lies in its retrospective and single-center design. Future prospective research is needed to confirm our findings. While this represents the largest investigation to date into cycle outcomes related to follicle size at ovulation trigger in modified NC-FETs, the sample sizes in certain subgroups were relatively small, which may limit the statistical power to identify differences among some groups. Therefore, caution is advised in the interpretation of these findings. Additionally, an intensive LPS was used, potentially reducing the external validity of our findings. WIDER IMPLICATIONS OF THE FINDINGS: The current data suggest that with the administration of an intensive LPS, the hCG trigger can be given across a wide range of follicle sizes, from above 10 to 18 mm or larger in diameter, in modified NC-FETs. This approach not only simplifies patient monitoring but also offers greater flexibility and autonomy in scheduling the date of embryo transfer. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the National Natural Science Foundation of China (grant no. 82171685). The authors declare that they have no competing interests. TRIAL REGISTRATION NUMBER: N/A.
- 7 June 2025
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2025 (3) , hoaf047
Open AccessPregnancy and perinatal outcomes after modified natural cycle-frozen embryo transfers according to size of the dominant follicle on the hCG trigger day
STUDY QUESTION: Is there an association between the dominant follicle size on the day of the hCG ovulation trigger and reproductive, obstetric, and perinatal outcomes in modified natural cycle-frozen embryo transfer (NC-FET) cycles in which intensive luteal phase support (LPS) was utilized? SUMMARY ANSWER: The dominant follicle size on the day of triggering, ranging from above 10 to 18 mm or larger, was not associated with negative live birth or perinatal outcomes in modified NC-FETs when an intensive LPS was provided. WHAT IS KNOWN ALREADY: There is growing evidence concerning the optimal timing for triggering final oocyte maturation during IVF ovarian stimulation cycles to obtain mature oocytes. However, a consensus on the ideal follicle size for administering hCG in modified NC-FETs has yet to be established. Interestingly, it has been suggested that the presence of a mature oocyte may not be necessary for FET. STUDY DESIGN, SIZE, DURATION: A retrospective cohort study was conducted at a university-affiliated reproductive medicine center. The study included women with regular menstrual cycles who underwent autologous modified NC-FETs between 2013 and 2023 for potential analysis. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients were categorized into eight groups based on the size of the dominant follicle at the time of hCG administration: <12, 12–12.9, 13–13.9, 14–14.9, 15–15.9, 16–16.9, 17–17.9, and ≥18 mm. The primary outcome measured was the live birth rate (LBR), while secondary outcomes included the rates of positive pregnancy tests, implantation, clinical pregnancy, and pregnancy loss, as well as perinatal and obstetric complications. A generalized estimating equation logistic regression model was employed to account for the clustered nature of the data and to adjust for potential confounding factors. The group with a follicle size ≥18 mm was designated as the reference group in the logistic regression analyses. An intensive LPS, consisting of 40 mg dydrogesterone plus 400 mg vaginal progesterone, was adopted. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 14 431 cycles that met the inclusion criteria were analyzed. The LBRs were similar across the eight groups. Furthermore, there were no significant differences in LBRs when the reference group was compared to the other follicle-size categories in the unadjusted models. Even after adjusting for several key confounders, the LBRs remained comparable between the study cohorts and the reference controls. Additionally, other reproductive parameters, such as rates of positive pregnancy tests, implantation, clinical pregnancy, and pregnancy loss, showed similar results between the control group and all other groups in both the unadjusted and confounder-adjusted analyses. Finally, pregnancies derived from the other follicle-size groups did not show increased risks of adverse perinatal or obstetric outcomes when compared to the reference group, both before and after adjustment for covariates. LIMITATIONS, REASONS FOR CAUTION: The primary limitation of the current study lies in its retrospective and single-center design. Future prospective research is needed to confirm our findings. While this represents the largest investigation to date into cycle outcomes related to follicle size at ovulation trigger in modified NC-FETs, the sample sizes in certain subgroups were relatively small, which may limit the statistical power to identify differences among some groups. Therefore, caution is advised in the interpretation of these findings. Additionally, an intensive LPS was used, potentially reducing the external validity of our findings. WIDER IMPLICATIONS OF THE FINDINGS: The current data suggest that with the administration of an intensive LPS, the hCG trigger can be given across a wide range of follicle sizes, from above 10 to 18 mm or larger in diameter, in modified NC-FETs. This approach not only simplifies patient monitoring but also offers greater flexibility and autonomy in scheduling the date of embryo transfer. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the National Natural Science Foundation of China (grant no. 82171685). The authors declare that they have no competing interests. TRIAL REGISTRATION NUMBER: N/A.
- 22 March 2025
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 51 (4) , 104973
The effect of peak follicular oestradiol on pregnancy outcomes in modified natural-frozen embryo transfers in 11,321 cycles
- 22 March 2025
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 51 (4) , 104973
The effect of peak follicular oestradiol on pregnancy outcomes in modified natural-frozen embryo transfers in 11,321 cycles
- 17 January 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (2) , 589-598
Infection with SARS-CoV-2 during the first trimester did not adversely impact perinatal and obstetric outcomes subsequent to in vitro fertilization with frozen embryo transfer: a retrospective cohort study
Purpose To investigate the impact of first-trimester COVID-19 infection on the perinatal and obstetric outcomes following in vitro fertilization-frozen embryo transfer. Methods This retrospective study was conducted at a university-affiliated IVF center. The infection group included women who contracted SARS-CoV-2 during the first trimester following frozen embryo transfer in China’s initial pandemic wave that occurred from 7 December 2022 to 7 January 2023. The control group consisted of pregnant women from the pre-pandemic period, considering the widespread incidence of the disease among the Chinese population during such a large outbreak. The primary outcome was perinatal and obstetric parameters. Results A total of 346 pregnant women who tested positive for COVID-19 during the first trimester were included in the analysis, while the control group comprised 705 uninfected women (pre-COVID-19 controls). Perinatal outcomes, such as preterm birth, low birthweight, birthweight Z scores, macrosomia, small for gestational age, large for gestational age, and congenital malformations, showed no significant differences between the infected and control groups in both the unadjusted and confounder-adjusted logistic regression models. Additionally, there were no significant differences between the groups concerning obstetric complications, including gestational diabetes mellitus, hypertensive disorders of pregnancy, placenta previa, preterm premature rupture of the membrane, and mode of delivery. Conclusion The current study demonstrated that contracting COVID-19 during the first trimester did not adversely impact future obstetric and perinatal outcomes following in vitro fertilization-frozen embryo transfer. This data holds practical significance and offers essential insights for reproductive specialists and obstetricians advising expectant mothers.
- 17 January 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (2) , 589-598
Infection with SARS-CoV-2 during the first trimester did not adversely impact perinatal and obstetric outcomes subsequent to in vitro fertilization with frozen embryo transfer: a retrospective cohort study
Purpose To investigate the impact of first-trimester COVID-19 infection on the perinatal and obstetric outcomes following in vitro fertilization-frozen embryo transfer. Methods This retrospective study was conducted at a university-affiliated IVF center. The infection group included women who contracted SARS-CoV-2 during the first trimester following frozen embryo transfer in China’s initial pandemic wave that occurred from 7 December 2022 to 7 January 2023. The control group consisted of pregnant women from the pre-pandemic period, considering the widespread incidence of the disease among the Chinese population during such a large outbreak. The primary outcome was perinatal and obstetric parameters. Results A total of 346 pregnant women who tested positive for COVID-19 during the first trimester were included in the analysis, while the control group comprised 705 uninfected women (pre-COVID-19 controls). Perinatal outcomes, such as preterm birth, low birthweight, birthweight Z scores, macrosomia, small for gestational age, large for gestational age, and congenital malformations, showed no significant differences between the infected and control groups in both the unadjusted and confounder-adjusted logistic regression models. Additionally, there were no significant differences between the groups concerning obstetric complications, including gestational diabetes mellitus, hypertensive disorders of pregnancy, placenta previa, preterm premature rupture of the membrane, and mode of delivery. Conclusion The current study demonstrated that contracting COVID-19 during the first trimester did not adversely impact future obstetric and perinatal outcomes following in vitro fertilization-frozen embryo transfer. This data holds practical significance and offers essential insights for reproductive specialists and obstetricians advising expectant mothers.
- Open Access
- 1 January 2025
- Published by Wiley in Reproductive Medicine and Biology
- Vol. 24 (1)
Influence of Medical Versus Surgical Evacuation of Early Miscarriage Loss on Reproductive Outcomes of Women in Subsequent FET Cycle
Purpose: To investigate how two methods for managing early miscarriage after frozen embryo transfer (FET) cycles impact live birth rates and other reproductive and perinatal outcomes in subsequent FET cycles without preimplantation genetic testing for aneuploidy (PGT‐A). Methods: This retrospective cohort study of women undergoing FET cycles (January 2016–December 2022) in our department who experienced early miscarriage diagnosed by transvaginal ultrasound examined the impact of medical versus surgical evacuation on subsequent live birth rates (LBR). Results: Analysis of 1685 women revealed no significant differences in implantation, miscarriage, preterm birth, obstetric complications, or neonatal disease rates between groups. However, the surgical management group had lower positive pregnancy test, clinical pregnancy, and live birth rates, and higher cesarean rates. While adjustments for confounders eliminated the significance of differences in positive pregnancy tests and clinical pregnancies, lower live birth rates (aOR 0.80, 95% CI: 0.65–0.99) and higher cesarean rates (aOR 1.84, 95% CI: 1.19–2.84) persisted. The surgical group also showed significantly reduced endometrial thickness in subsequent cycles. Conclusion: Subsequent FET cycles after surgical miscarriage evacuation show lower live birth rates and thinner endometrial lining than those following medical evacuation; surgical evacuation also correlates with increased cesarean section rates in non‐PGT‐A FET cycles.
- 1 January 2025
- Published by Wiley in Reproductive Medicine and Biology
- Vol. 24 (1)
Open AccessInfluence of Medical Versus Surgical Evacuation of Early Miscarriage Loss on Reproductive Outcomes of Women in Subsequent FET Cycle
Purpose: To investigate how two methods for managing early miscarriage after frozen embryo transfer (FET) cycles impact live birth rates and other reproductive and perinatal outcomes in subsequent FET cycles without preimplantation genetic testing for aneuploidy (PGT‐A). Methods: This retrospective cohort study of women undergoing FET cycles (January 2016–December 2022) in our department who experienced early miscarriage diagnosed by transvaginal ultrasound examined the impact of medical versus surgical evacuation on subsequent live birth rates (LBR). Results: Analysis of 1685 women revealed no significant differences in implantation, miscarriage, preterm birth, obstetric complications, or neonatal disease rates between groups. However, the surgical management group had lower positive pregnancy test, clinical pregnancy, and live birth rates, and higher cesarean rates. While adjustments for confounders eliminated the significance of differences in positive pregnancy tests and clinical pregnancies, lower live birth rates (aOR 0.80, 95% CI: 0.65–0.99) and higher cesarean rates (aOR 1.84, 95% CI: 1.19–2.84) persisted. The surgical group also showed significantly reduced endometrial thickness in subsequent cycles. Conclusion: Subsequent FET cycles after surgical miscarriage evacuation show lower live birth rates and thinner endometrial lining than those following medical evacuation; surgical evacuation also correlates with increased cesarean section rates in non‐PGT‐A FET cycles.